Clinical efficacy of zonisamide in Lennox-Gastaut syndrome: Korean multicentric experience

Su Jeong You, Hoon Chul Kang, Heung Dong Kim, Hyun Sug Lee, Tae Sung Ko

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Purpose: To evaluate the efficacy and safety of zonisamide (ZNS) as long-term adjunctive therapy in children with Lennox-Gastaut syndrome (LGS). Method: We evaluated the seizure frequency, cognitive outcomes, and side effects of 62 LGS patients maintained on ZNS for at least 12 months in three tertiary centers. Results: Of the 62 LGS patients maintained on ZNS, 3 (4.8%) had 100% seizure control; 14 (22.6%) had >75% to <100% reduction in seizure frequency; 15 (24.2%) had >50% to <75% reduction in seizure frequency; 6 (9.7%) had >0% to <50% reduction in seizure frequency, and 24 (38.7%) had no seizure reduction. Seizure outcomes were not related to seizure types or etiologies. Adverse events included somnolence and anorexia, but all were transient and successfully managed by careful follow-up. Conclusion: Our results indicate that adjunctive treatment with ZNS is safe and effective in pediatric LGS patients.

Original languageEnglish
Pages (from-to)287-290
Number of pages4
JournalBrain and Development
Volume30
Issue number4
DOIs
Publication statusPublished - 2008 Apr 1

Fingerprint

zonisamide
Seizures
Anorexia
Lennox Gastaut Syndrome

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

@article{6e179fe9957e43fd8d4c55e980e6dfa0,
title = "Clinical efficacy of zonisamide in Lennox-Gastaut syndrome: Korean multicentric experience",
abstract = "Purpose: To evaluate the efficacy and safety of zonisamide (ZNS) as long-term adjunctive therapy in children with Lennox-Gastaut syndrome (LGS). Method: We evaluated the seizure frequency, cognitive outcomes, and side effects of 62 LGS patients maintained on ZNS for at least 12 months in three tertiary centers. Results: Of the 62 LGS patients maintained on ZNS, 3 (4.8{\%}) had 100{\%} seizure control; 14 (22.6{\%}) had >75{\%} to <100{\%} reduction in seizure frequency; 15 (24.2{\%}) had >50{\%} to <75{\%} reduction in seizure frequency; 6 (9.7{\%}) had >0{\%} to <50{\%} reduction in seizure frequency, and 24 (38.7{\%}) had no seizure reduction. Seizure outcomes were not related to seizure types or etiologies. Adverse events included somnolence and anorexia, but all were transient and successfully managed by careful follow-up. Conclusion: Our results indicate that adjunctive treatment with ZNS is safe and effective in pediatric LGS patients.",
author = "You, {Su Jeong} and Kang, {Hoon Chul} and Kim, {Heung Dong} and Lee, {Hyun Sug} and Ko, {Tae Sung}",
year = "2008",
month = "4",
day = "1",
doi = "10.1016/j.braindev.2007.09.004",
language = "English",
volume = "30",
pages = "287--290",
journal = "Brain and Development",
issn = "0387-7604",
publisher = "Elsevier",
number = "4",

}

Clinical efficacy of zonisamide in Lennox-Gastaut syndrome : Korean multicentric experience. / You, Su Jeong; Kang, Hoon Chul; Kim, Heung Dong; Lee, Hyun Sug; Ko, Tae Sung.

In: Brain and Development, Vol. 30, No. 4, 01.04.2008, p. 287-290.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical efficacy of zonisamide in Lennox-Gastaut syndrome

T2 - Korean multicentric experience

AU - You, Su Jeong

AU - Kang, Hoon Chul

AU - Kim, Heung Dong

AU - Lee, Hyun Sug

AU - Ko, Tae Sung

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Purpose: To evaluate the efficacy and safety of zonisamide (ZNS) as long-term adjunctive therapy in children with Lennox-Gastaut syndrome (LGS). Method: We evaluated the seizure frequency, cognitive outcomes, and side effects of 62 LGS patients maintained on ZNS for at least 12 months in three tertiary centers. Results: Of the 62 LGS patients maintained on ZNS, 3 (4.8%) had 100% seizure control; 14 (22.6%) had >75% to <100% reduction in seizure frequency; 15 (24.2%) had >50% to <75% reduction in seizure frequency; 6 (9.7%) had >0% to <50% reduction in seizure frequency, and 24 (38.7%) had no seizure reduction. Seizure outcomes were not related to seizure types or etiologies. Adverse events included somnolence and anorexia, but all were transient and successfully managed by careful follow-up. Conclusion: Our results indicate that adjunctive treatment with ZNS is safe and effective in pediatric LGS patients.

AB - Purpose: To evaluate the efficacy and safety of zonisamide (ZNS) as long-term adjunctive therapy in children with Lennox-Gastaut syndrome (LGS). Method: We evaluated the seizure frequency, cognitive outcomes, and side effects of 62 LGS patients maintained on ZNS for at least 12 months in three tertiary centers. Results: Of the 62 LGS patients maintained on ZNS, 3 (4.8%) had 100% seizure control; 14 (22.6%) had >75% to <100% reduction in seizure frequency; 15 (24.2%) had >50% to <75% reduction in seizure frequency; 6 (9.7%) had >0% to <50% reduction in seizure frequency, and 24 (38.7%) had no seizure reduction. Seizure outcomes were not related to seizure types or etiologies. Adverse events included somnolence and anorexia, but all were transient and successfully managed by careful follow-up. Conclusion: Our results indicate that adjunctive treatment with ZNS is safe and effective in pediatric LGS patients.

UR - http://www.scopus.com/inward/record.url?scp=40449142934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40449142934&partnerID=8YFLogxK

U2 - 10.1016/j.braindev.2007.09.004

DO - 10.1016/j.braindev.2007.09.004

M3 - Article

C2 - 17959327

AN - SCOPUS:40449142934

VL - 30

SP - 287

EP - 290

JO - Brain and Development

JF - Brain and Development

SN - 0387-7604

IS - 4

ER -